GlassScriptPhysician profile
Hannah Jumper
NPI 1730584038
$995.09
in general payments reported to CMS, 2019-2025
19 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $187 · 2023: $210 · 2024: $478 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $243.47 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Medtronic, INC. | $144.30 | 2023-2025 | Reliatack, Progrip, Maxtack |
| Ethicon US, LLC | $98.55 | 2022-2024 | Echelon; Endopath, Surgicel Nu-Knit, Vistaseal |
| Convatec INC. | $62.91 | 2024 | |
| Merck Sharp & Dohme LLC | $57.02 | 2023-2024 | Zerbaxa, Recarbrio |
| Atricure, INC. | $50.19 | 2022 | |
| Octapharma USA, INC. | $43.89 | 2024 | Balfaxar |
| Integra Lifesciences Corporation | $37.90 | 2024-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Takeda Pharmaceuticals U.S.A., INC. | $35.84 | 2022 | |
| Avita Medical Americas, LLC | $33.77 | 2025 | Cohealyx, Permeaderm, Recell |
| Baxter Healthcare | $31.94 | 2023 | Floseal |
| Kowa Pharmaceuticals America, INC. | $24.92 | 2022 | |
| Sanara Medtech INC. | $21.95 | 2023 | Celleraterx |
| Ambu INC. | $21.04 | 2022 | |
| La Jolla Pharmaceutical Company | $20.82 | 2024 | Giapreza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $20.52 | 2022 | |
| Aroa Biosurgery Incorporated | $18.02 | 2025 | |
| Boston Scientific Corporation | $17.01 | 2022 | |
| Rigel Pharmaceuticals, INC. | $11.03 | 2024 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Jumper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.